Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Harshani Lawrence

H. Lee Moffitt Cancer Ctr & Res Inst, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

TechnoGenesys, Inc.

Disclosed Value
Listed Reason
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution

NA

Listed Research Project
Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer

Project Narrative Presence of elevated AR mRNA levels in spite of prolonged androgen receptor (AR) antagonist treatment in castration resistant prostate cancer (CRPC) is a paradox that has mystified researchers. This proposal uncovers a novel mechanism of auto- regulation of AR transcription wherein AR protein coordinates functionally with ACK1 tyrosine kinase to modify chromatin within the AR gene. Significantly, these data have exposed an Achilles' heel for targeting new treatment strategies in CRPCs. Our preliminary data indicates that reversal of these epigenetic marks by a novel ACK1 inhibitor (R)-9bMS, that we have developed, opens up a new therapeutic option for this essentially incurable malignancy. This proposal will perform detailed mechanistic & in vivo studies to test efficacy of (R)-9b as novel epigenetic inhibitors that suppress both AR and AR-V7 transcription overcoming CRPC tumor growth.

Filed on March 21, 2017.

Tell us what you know about Harshani Lawrence's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page